Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WARNER-LAMBERT SECOND QUARTER NET ADVANCES 12% ON U.S. Rx BUSINESS' STRENGTH

Executive Summary

Parke-Davis' U.S. Rx drug business helped fuel a 12% jump, to $62 mil., in Warner-Lambert's second quarter net income, the company reported July 31. Paced by Lopid, Procan SR, ERYC, and Meclomen, Parke-Davis U.S. sales also advanced 12%. Overall, the firm said, "sales of Lopid, the number one drug in its category, increased sharply over last year's second quarter. Also during the quarter, Procan SR continued to advance its position as the leading prescribed antiarrhythmic agent." Worldwide, Warner-Lambert's volume edged up 1.8%, to $797 mil. The gain would have been 5% if foreign currency effects were excluded. In addition to the strong performance of the U.S. ethical drug business, Warner-Lambert attributed the net income increase to improved margins and a lower effective tax rate. In the strong U.S. economy, the firm noted, all segments of Warner-Lambert's domestic business advanced. OTC sales advanced among a number of Warner-Lambert's product categories. Benylin "achieved a record market share," the firm asserted. "Listerine antiseptic and E.P.T. early pregnancy test registered solid increases in both sales and market share. Two improved E.P.T. test kits introduced earlier in the year contributed to the sharp gain in E.P.T. sales." Chart omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel